Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 4
Submit an article Journal homepage
209
Views
15
CrossRef citations to date
0
Altmetric
Letters to the Editor

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States

Amer M. ZeidanSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; Correspondence[email protected]
,
Rong WangCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;
,
Cary P. GrossCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Steven D. GoreSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Scott F. HuntingtonSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; ;Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA;
,
Thomas PrebetSection of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA;
,
Gregory A. AbelDivision of Population Sciences, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA;
,
Amy J. DavidoffCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA
&
Xiaomei MaCancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA; ;Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA;
show all
Pages 982-985 | Received 24 May 2016, Accepted 13 Jul 2016, Published online: 25 Aug 2016

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Amy J. Davidoff, Xin Hu, Jan Philipp Bewersdorf, Rong Wang, Nikolai A. Podoltsev, Scott F. Huntington, Steven D. Gore, Xiaomei Ma & Amer M. Zeidan. (2020) Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study. Leukemia & Lymphoma 61:5, pages 1178-1187.
Read now
Rory M. Shallis, Nora Chokr, Maximilian Stahl, Alexander B. Pine & Amer M. Zeidan. (2018) Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Review of Hematology 11:9, pages 715-726.
Read now
Amer M. Zeidan. (2018) Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?. Leukemia & Lymphoma 59:5, pages 1030-1032.
Read now

Articles from other publishers (12)

Sabine Blum, Gerasimos Tsilimidos, Helena Bresser & Michael Lübbert. (2022) Role of Bcl‐2 inhibition in myelodysplastic syndromes. International Journal of Cancer 152:8, pages 1526-1535.
Crossref
Razan Mohty, Rama Al Hamed, Ali Bazarbachi, Eolia Brissot, Arnon Nagler, Amer Zeidan & Mohamad Mohty. (2022) Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease. Journal of Hematology & Oncology 15:1.
Crossref
Amer M. ZeidanIsaac BossC. L. BeachWilbert B. CopelandEthan ThompsonBrian A. Fox, Vanessa E. HasleKen Ogasawara, James CavenaghLewis R. SilvermanMaria Teresa Voso, Andrzej HellmannMar Tormo, Tim O’ConnorAlessandro PrevitaliShelonitda RoseGuillermo Garcia-Manero. (2022) A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes. Blood Advances 6:7, pages 2207-2218.
Crossref
Carolien Duetz, David G. J. Cucchi, Tobias B. Polak, Jeroen J. W. M. Janssen, Gert J. Ossenkoppele, Elihu H. Estey & Arjan A. van de Loosdrecht. (2021) The wider perspective: twenty years of clinical trials in myelodysplastic syndromes. British Journal of Haematology 196:2, pages 329-335.
Crossref
Amer M Zeidan, Tehseen Salimi & Robert S Epstein. (2021) Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?. Future Oncology 17:36, pages 5163-5175.
Crossref
Amer M. Zeidan, Rory M. Shallis, Rong Wang, Amy Davidoff & Xiaomei Ma. (2019) Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Reviews 34, pages 1-15.
Crossref
Rory M. Shallis & Amer M. Zeidan. (2018) More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 18:1.
Crossref
Marlise R. Luskin & Gregory A. Abel. (2018) Management of older adults with myelodysplastic syndromes (MDS). Journal of Geriatric Oncology 9:4, pages 302-307.
Crossref
Amer M. Zeidan, Maximilian Stahl, Michelle DeVeaux, Smith Giri, Scott Huntington, Nikolai Podoltsev, Rong Wang, Xiaomei Ma, Amy J. Davidoff & Steven D. Gore. (2018) Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?. Blood Cancer Journal 8:6.
Crossref
Amer M. Zeidan, Maximilian Stahl, Xin HuRong Wang, Scott F. Huntington, Nikolai A. PodoltsevSteven D. Gore, Xiaomei Ma & Amy J. Davidoff. (2018) Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 131:7, pages 818-821.
Crossref
Amer M. Zeidan, Maximilian Stahl, Mikkael A. Sekeres, David P. Steensma, Rami S. Komrokji & Steven D. Gore. (2017) A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer 123:19, pages 3662-3672.
Crossref
A M Zeidan, N Al Ali, J Barnard, E Padron, J E Lancet, M A Sekeres, D P Steensma, A DeZern, G Roboz, E Jabbour, G Garcia-Manero, A List & R Komrokji. (2017) Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium. Leukemia 31:6, pages 1391-1397.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.